Stay updated on Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial page.

Latest updates to the Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov page's footer displays an updated site revision label, from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check9 days agoChange DetectedThe clinical trial record for pembrolizumab with concurrent radiation in previously treated carcinoma of unknown primary is displayed, including its study details, participation criteria, and results-related information.SummaryDifference56%

- Check15 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0 on the 403 error page.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide NIH banner announces a terminology transition from “Artificial Intelligence” to “Super Intelligence,” and the site revision label updates from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study page now renders a 403 Forbidden error with HTML indicating restricted access, and the visible study content appears removed or hidden as a result.SummaryDifference20%

Stay in the know with updates to Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial page.